While cannabis itself has an ancient traditional history, CBD oil as a specific, isolated, commercially marketed product is a genuinely modern phenomenon, emerging largely after changes to hemp cultivation laws beginning in the 2010s. This rapid commercialization significantly outpaced the available clinical research.
CBD's chemical distinction from THC — it does not produce intoxicating effects — has been central to its mainstream commercial acceptance and its research focus on non-psychoactive applications like anxiety and pain.
CBD has real, meta-analysis-level evidence for anxiety specifically. A 2024 systematic review and meta-analysis of 8 studies (316 participants) covering generalized anxiety disorder, social anxiety disorder, and PTSD found "a substantial significant impact of CBD on anxiety with a considerable effect size." The study authors were nonetheless appropriately cautious, noting the "limited size of the clinical sample" and calling for additional trials.
For CBD's other major popularly claimed use — pain — the evidence remains considerably more preliminary. Available human research consists largely of small open-label, uncontrolled pilot studies and several registered trials that were terminated or have unknown/incomplete status. Given a genuine, if modest-sized, meta-analysis specifically supporting anxiety, but considerably thinner evidence for pain, "Limited-Moderate" is the accurate, application-specific rating.
Not applicable in the traditional sense — extracted from hemp plant material using modern solvent or CO2 extraction methods, standardized for CBD content.